Abattis Bioceuticals Corp. (OTC: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, recently entered into a consulting with Phytalytics LLC to establish a WSLCB-certified analytics laboratory testing license.
Notably, Dr. Michelle Sexton, Founder and CEO of Phytalabs, was instrumental in developing the checklist and protocols for the Certification Process for an analytics lab for the Washington State Liquor Control Board, which approves State Licensing of adult and medicinal marijuana. The relationship is a continuation of Abattis’ commitment to the ‘GDERS’ model, strengthening the sciences that ensure safe, efficacious, quality products.
Read the entire press release discussing the venture here:
Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE:ATT), wishes to announce that it has entered into Consulting Agreements with the principals from Phytalytics LLC, (D.B.A. PhytoLabs.com) of Kenmore, Washington USA whereby the consultants will make application to WSLCB (Washington State Liquor Control Board) for an analytics laboratory testing license. Phytalytics will provide government mandated testing of cannabis and all other cannabis related derivatives under State Initiative 502 (“SI502”).
The WSLCB has released the accreditation criteria that third party testing labs must meet in order to be certified to test useable marijuana and marijuana products” under the 1-502 regulatory system. The WSLCB has contracted with the Center for Laboratory Sciences on the Campus of the Columbia Basin College to conduct the certification process.
Phytalabs and its principals, Dr. Michelle Sexton, Dr. Kaleb Lund and, Lauren Hilty, CPA, are at the forefront of providing regulated testing and quality assurance for cannabis and its derivatives in the burgeoning legal marijuana marketplace in North America.
Dr. Michelle Sexton, Founder and CEO of Phytalabs, was instrumental in developing the checklist and protocols for the Certification Process for an analytics lab for the Washington State Liquor Control Board, which approves State Licensing of adult and medicinal marijuana. Dr. Sexton was the editor and technical advisor on the Monograph of American Herbal Pharmacopoeia. Dr. Sexton is also a board member of the Americans for Safe Access Foundation.
Dr. Sexton stated, “The opportunity to partner with the Abattis Team is a highlight of my career. I have been passionate about furthering the historic mission of setting the standard for quality control of Cannabis and related products which began in Washington State.”
Dr. Kaleb Lund, is the Science Director of Phytalabs and has 10 years of analytical testing experience of herbal supplements. He is an Assistant Professor in the Department of Botanical Medicine at the leading institution of naturopathic medicine, Bastyr University in Kenmore. He teaches classes on GMP regulation, botanical authentication, research and pharmacognosy (the study of medicine derived from natural sources). He oversees the laboratory and testing protocols at Phytalabs. “I am very excited about the prospect of maximizing the quality of botanicals from seed all the way to formulated products. We are breaking new ground in Washington State with Cannabis and I feel that this partnership with Abattis will help us to set the standards for quality and safety of this growing industry.” stated Dr. Kaleb Lund.
Ms. Lauren Hilty, CPA, the Treasurer and Accountant has been a consultant with the Federal Depository Insurance Corporation (FDIC) to establish the infrastructure for U.S. banking institutions to provide banking and transactional services to the legal marijuana industry. Her role in Phytalabs is to ensure compliance with State and federal banking and tax laws and regulations for the cannabis business within state and federal regulations.
Mike Withrow, CEO of Abattis Bioceuticals Corp., stated, “We are really looking forward to working with our new Analytics Lab Testing Team and Ms. Hilty which is led by Dr. Sexton in establishing the US footprint for Abattis starting in Washington State. Our new team is a perfect fit and a welcome addition to the Abattis group of companies. We initially learned about Dr. Sexton through our financial sponsorship of the historic AHP Monograph for Cannabis in March 2012. This relationship is a continuation of our commitment to the ‘GDERS’ model by strengthening the sciences that ensure safe, efficacious, quality products”.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law’s of Canada and Foreign Jurisdictions. For more information, visit the Company’s website atwww.abattis.com.
For further information, contact the Company’s CEO, Michael Withrow at (778) 896-
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis for the nine months ended June 30, 2013 and filed on August 29, 2013 and for the year ended September 30, 2012 and filed on January 28, 2013 under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
CannabisFN.com, owned by TDM Financial, is a leading provider of cannabis news and insights. CannabisFN.com may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For a full disclaimer, click here SECFilings.com/disclaimer.aspx.